Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABT-494 plus methotrexate in anti-TNF inadequate responder rheumatoid arthritis
NL-OMON40747Phase 2Withdrawn
- Sponsor
- AbbVie Inc.
- Start
- Feb 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of upadacitinib in rheumatoid arthritis (RA) (5 arms), sponsored by AbbVie Inc. Primary endpoint: ACR20 response rate at Week 12. Planned start Feb 2014; status: withdrawn.
02
Drugs
upadacitinib
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NL-OMON40747.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON40747.